MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

A

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

41.38 -0.02

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

39.05

Макс.

42.44

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

3.2M

-21M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

-0.39% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

2 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

669M

2.5B

Предыдущая цена открытия

41.4

Предыдущая цена закрытия

41.38

Новостные настроения

By Acuity

50%

50%

159 / 361 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 янв. 2026 г., 23:43 UTC

Обсуждения рынка

Gold Consolidates; May Face Technical Correction -- Market Talk

20 янв. 2026 г., 23:42 UTC

Обсуждения рынка

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 янв. 2026 г., 23:41 UTC

Отчет

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 янв. 2026 г., 23:29 UTC

Обсуждения рынка

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 янв. 2026 г., 23:26 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

20 янв. 2026 г., 23:26 UTC

Обсуждения рынка

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 янв. 2026 г., 22:45 UTC

Приобретения, слияния, поглощения

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 янв. 2026 г., 22:45 UTC

Приобретения, слияния, поглощения

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 янв. 2026 г., 22:44 UTC

Приобретения, слияния, поглощения

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 янв. 2026 г., 22:44 UTC

Приобретения, слияния, поглощения

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 янв. 2026 г., 22:43 UTC

Приобретения, слияния, поглощения

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 янв. 2026 г., 22:43 UTC

Приобретения, слияния, поглощения

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 янв. 2026 г., 22:27 UTC

Приобретения, слияния, поглощения

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 янв. 2026 г., 22:25 UTC

Приобретения, слияния, поглощения

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 янв. 2026 г., 22:21 UTC

Приобретения, слияния, поглощения

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 янв. 2026 г., 22:20 UTC

Приобретения, слияния, поглощения

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 янв. 2026 г., 22:19 UTC

Приобретения, слияния, поглощения

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 янв. 2026 г., 22:18 UTC

Отчет

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 янв. 2026 г., 22:17 UTC

Приобретения, слияния, поглощения

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 янв. 2026 г., 22:16 UTC

Приобретения, слияния, поглощения

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 янв. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 янв. 2026 г., 22:15 UTC

Приобретения, слияния, поглощения

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 янв. 2026 г., 22:13 UTC

Приобретения, слияния, поглощения

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 янв. 2026 г., 22:11 UTC

Приобретения, слияния, поглощения

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 янв. 2026 г., 22:10 UTC

Приобретения, слияния, поглощения

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 янв. 2026 г., 22:08 UTC

Приобретения, слияния, поглощения

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 янв. 2026 г., 22:07 UTC

Приобретения, слияния, поглощения

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 янв. 2026 г., 22:06 UTC

Отчет

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 янв. 2026 г., 22:00 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

ESG Roundup: Market Talk

20 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

-0.39% падение

Прогноз на 12 месяцев

Средняя 41.25 USD  -0.39%

Максимум 43 USD

Минимум 39 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

159 / 361Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat